Paper summaries & Press releases


VIB Blog •

Better, cheaper, easier, HyDrop

A Leuven research team led by Stein Aerts and the single-cell experts at the VIB-KU Leuven Center for Brain & Disease Research has developed HyDrop: an optimized open-source protocol using dissolvable hydrogel beads. HyDrop reduces both the cost and labor intensity of existing open-source single-cell sequencing methods and offers improved sensitivity. The new method, published in eLife, will accelerate the implementation of single-cell analysis in a variety of research fields.
VIB Persbericht •

“Yes, we still need animals”

‘Do we still need animals?’ is the provocative title of a meta-analysis on methods and models used in Alzheimer’s and Parkinson’s disease research, completed by an interdisciplinary team of researchers at VIB, KU Leuven, imec and VITO. After screening thousands of abstracts and papers, mapping both animal-based and animal-free methods, the authors conclude that calls to halt all animal research are premature, and that a more nuanced approach to monitor animal use is needed to inform policy discu
VIB News •

Landmark fly brain study deciphers the genomic regulatory code behind neuronal diversity

The single-cell revolution is revealing more and more fine-grained insights into the biology of living organisms. The deep learning (AI) revolution adds unprecedented computational power to analyze these “big data”. A research team led by Stein Aerts (VIB-KU Leuven) has combined these two revolutions to sketch a new picture of gene regulation in all cells of the fruit fly brain, using deep learning to reveal how specific pieces of DNA steer neuronal identity, from birth to maturity.
VIB News •

Digging for brain disease biomarkers with innovative proteomics

Two VIB research teams join forces to look for biomarkers in blood and cerebrospinal fluid samples of people living with frontotemporal degeneration. This brain disease causes dementia, usually at a relatively young age. Backed by 2 million USD in funding from the US Department of Defense, Rosa Rademakers and Kris Gevaert plan to enrich low-abundance disease-related proteins using an innovative proteomic workflow.
VIB News •

PIKfyve sorts tau aggregates to lysosomes

Tau aggregates are found in brains affected with different neurodegenerative diseases, including Alzheimer’s disease, but how exactly they spread across more and more brain regions has remained unclear. A collaboration between the Annaert lab (VIB-KU Leuven) and the Neuroscience Therapeutic Area at Janssen Pharmaceutica has yielded important new insights into the molecular mechanisms that govern the transmission of tau aggregates.
NERF •

opto-fUSI: Embracing the complexity of the brain

When you spot danger, you better act—fast! A team of researchers led by Karl Farrow and Alan Urban from NERF sheds new light on how the brain processes visual information to guide behavior. By combining optogenetics with functional ultrasound imaging in a so called opto-fUSI method, they were able to reveal the networks in the brain that are active when animals try to avoid danger. The results have been published in this week’s edition of Neuron.
Load More Articles

Science life

VIB News •

Mini-documentary asks kids what it’s like to have an immune disorder

This week, patient organizations raise awareness for Primary Immune Deficiency, PID for short, a clinical term for hundreds of congenital disorders of the immune system. About 1 in 2000 children and adults have PID and therefore become ill much more often and more seriously than others. A team of Belgian researchers and clinicians wants to improve PID diagnostics and raise awareness for PID. In a new mini-documentary, they bring the story of children and young people with PID and addresses common misconceptions.
The Lancet Neurology •

Dementia and COVID-19: a health and research funding crisis

Neurological research is at a turning point. Emerging technological advances offer opportunities to understand brain function in health and disease in a way no one could have even dreamed of 5 years ago. With these advances, combined with new methods of targeting the brain with antisense therapy or therapeutic antibodies, we stand on the verge of breakthroughs in treating neurological diseases.
BioVox •

Liesbeth Aerts in Sydney - Belgian scientist living abroad

Until August 2017, Liesbeth Aerts lived in Sydney, where she worked as a dementia researcher at the University of New South Wales. She studied bio-engineering and neuroscience (in Belgium and in the UK, respectively) and did a PhD focused on the molecular mechanisms of Parkinson’s disease at VIB/KU Leuven. After a short stint in the US freelancing as a scientific editor, she moved to Sydney in 2015. There, she was involved in several ongoing longitudinal studies assessing cognitive decline in ol
VIB Reporter on the road •

When a 'like' is not enough

When you do research on neurodegenerative diseases as common and devastating as Alzheimer’s or Parkinson’s, it’s easy to pitch your work to a wider audience. Generally speaking, the people I meet are interested in what I do, or at least happy that I am interested in it on their behalf. Most of them are glad to know their tax money is invested in research that can help us understand and (hopefully) eventually cure the illnesses that they or their loved ones may suffer from. Consequently, most of